KR20220103961A - 약제학적 조합물 및 이의 용도 - Google Patents

약제학적 조합물 및 이의 용도 Download PDF

Info

Publication number
KR20220103961A
KR20220103961A KR1020227017523A KR20227017523A KR20220103961A KR 20220103961 A KR20220103961 A KR 20220103961A KR 1020227017523 A KR1020227017523 A KR 1020227017523A KR 20227017523 A KR20227017523 A KR 20227017523A KR 20220103961 A KR20220103961 A KR 20220103961A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227017523A
Other languages
English (en)
Korean (ko)
Inventor
주안 장
Original Assignee
씨스톤 파마슈티컬즈 (쑤저우) 컴퍼니 리미티드
씨스톤 파마슈티컬즈 (상하이) 컴퍼니 리미티드
씨스톤 파마슈티컬즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨스톤 파마슈티컬즈 (쑤저우) 컴퍼니 리미티드, 씨스톤 파마슈티컬즈 (상하이) 컴퍼니 리미티드, 씨스톤 파마슈티컬즈 filed Critical 씨스톤 파마슈티컬즈 (쑤저우) 컴퍼니 리미티드
Publication of KR20220103961A publication Critical patent/KR20220103961A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020227017523A 2019-11-11 2020-11-11 약제학적 조합물 및 이의 용도 Ceased KR20220103961A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019117155 2019-11-11
CNPCT/CN2019/117155 2019-11-11
PCT/CN2020/128083 WO2021093764A1 (en) 2019-11-11 2020-11-11 Pharmaceutical combination and use thereof

Publications (1)

Publication Number Publication Date
KR20220103961A true KR20220103961A (ko) 2022-07-25

Family

ID=75911807

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017523A Ceased KR20220103961A (ko) 2019-11-11 2020-11-11 약제학적 조합물 및 이의 용도

Country Status (11)

Country Link
US (1) US20220387417A1 (https=)
EP (1) EP4031179A4 (https=)
JP (1) JP2023500385A (https=)
KR (1) KR20220103961A (https=)
CN (1) CN114901309A (https=)
AU (1) AU2020383580A1 (https=)
BR (1) BR112022009042A2 (https=)
CA (1) CA3160526A1 (https=)
IL (1) IL292646A (https=)
MX (1) MX2022005034A (https=)
WO (1) WO2021093764A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3515938T (pt) * 2016-09-21 2025-04-10 Cstone Pharmaceuticals Shanghai Co Ltd Anticorpos monoclonais contra morte programada 1 (pd-1)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
TWI664977B (zh) * 2013-10-08 2019-07-11 第一三共股份有限公司 抗ｆｇｆｒ２抗體及其與其他藥劑之組合
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
CN114456269A (zh) * 2016-09-21 2022-05-10 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
PT3515938T (pt) * 2016-09-21 2025-04-10 Cstone Pharmaceuticals Shanghai Co Ltd Anticorpos monoclonais contra morte programada 1 (pd-1)
KR20210122319A (ko) * 2017-04-06 2021-10-08 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
CA3060514A1 (en) * 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
CN109731019B (zh) * 2019-03-07 2021-07-16 康赋葆(深圳)生物医药科技有限公司 一种具有化疗增效作用的组合物，包括组成、制备及应用
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法

Also Published As

Publication number Publication date
US20220387417A1 (en) 2022-12-08
CN114901309A (zh) 2022-08-12
MX2022005034A (es) 2022-05-16
EP4031179A1 (en) 2022-07-27
EP4031179A4 (en) 2023-10-04
WO2021093764A1 (en) 2021-05-20
AU2020383580A1 (en) 2022-05-12
JP2023500385A (ja) 2023-01-05
CA3160526A1 (en) 2021-05-20
IL292646A (en) 2022-07-01
BR112022009042A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
CN106459199B (zh) 抗-egfrviii抗体及其用途
JP2022091976A (ja) 抗ｓｔｅａｐ２抗体、抗体－薬物複合体、およびｓｔｅａｐ２とｃｄ３を結合する二重特異性抗原結合分子、ならびにそれらの使用
CN110799540B (zh) 多特异性抗体及其制备和使用方法
TWI854953B (zh) 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法
JP2020529863A (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2020515247A (ja) 抗ｏｘ４０抗体およびその使用
US12180281B2 (en) Anti-PD-1 antibodies and methods of treating cancer
CN112867507A (zh) 新型抗sirpa抗体
KR20160097336A (ko) 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
JP2016536020A (ja) 新規の抗クローディン抗体および使用方法
WO2022100590A1 (zh) 针对密蛋白18a2的adcc增强型人源化抗体及其应用
JP7479281B2 (ja) 抗ｏｘ４０抗体及びその用途
US20240002539A1 (en) Multispecific antibodies and uses thereof
KR20220133884A (ko) 항-mdr1 항체 및 이의 용도
JP2022514017A (ja) 医薬の組み合わせ
JP2014534965A (ja) コンパニオン診断を用いた乳癌の治療
CA3206413A1 (en) Antibodies against cd112r and uses thereof
KR20220103961A (ko) 약제학적 조합물 및 이의 용도
JP6673847B2 (ja) 癌治療に使用するためのアドレノメデュリンバインダー
HK40071307A (en) Pharmaceutical combination and use thereof
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
WO2025201493A1 (zh) Dll3结合分子及其用途
HK40114936A (zh) 新型抗fgfr2抗体
HK40019010B (zh) 多特异性抗体及其制备和使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601